Plus Therapeutics President & CEO, Marc Hedrick, MD, recently joined Nicole R. on the pharmaphorum podcast for an in-depth conversation about how the Company is developing next-generation radiotherapeutics designed to address some of the most difficult-to-treat cancers of the central nervous system (CNS).
In the episode, Dr. Hedrick outlines the scientific foundation and clinical progress of Plus Therapeutics’ novel platform technologies, which are engineered to deliver targeted radiation directly to tumors while minimizing damage to surrounding healthy tissue. This precision-based approach represents a meaningful shift in how radiopharmaceuticals may be used to manage complex CNS malignancies, including leptomeningeal metastases (LM) and glioblastoma (GBM).
A Growing Need for Better CNS Cancer Treatments
CNS cancers—particularly metastatic disease such as LM—remain associated with high morbidity, limited treatment options, and significant clinical management challenges. Traditional radiation therapies often struggle to reach tumor cells dispersed throughout the cerebrospinal fluid (CSF) or embedded within delicate CNS structures.
Plus Therapeutics’ radiotherapeutic candidates are being developed to overcome these challenges by combining:
-
Image-guided delivery
-
Highly localized therapeutic radiation
-
Customizable dosing strategies
-
Next-generation materials designed for CNS compatibility
During the interview, Dr. Hedrick discusses how these innovations have the potential to improve patient outcomes while expanding the boundaries of what radiopharmaceuticals can accomplish for CNS oncology.
Inside the Conversation: Key Topics Covered
The pharmaphorum discussion provides insight into several major areas of Plus Therapeutics’ work:
1. Advancements in Targeted Radiotherapeutics
How the Company’s novel platform technologies are engineered to maximize anti-tumor activity while maintaining a favorable safety profile.
2. Clinical Development in Leptomeningeal Metastases and Glioblastoma
Updates on ongoing and future clinical trials, including how Plus Therapeutics is working to create new solutions for patients with urgent unmet needs.
3. The Role of Diagnostics in CNS Cancer Care
How CNSide Diagnostics, the Company’s wholly owned subsidiary, is helping clinicians detect, enumerate, and characterize tumor cells in the CSF—an essential component for research, therapeutic decision-making, and real-time disease monitoring.
4. Vision for the Future of Radiotherapeutics
Dr. Hedrick shares how innovations in imaging, delivery techniques, and radiopharmaceutical design may unlock the next generation of precision CNS treatments.
Listen to the Full pharmaphorum Podcast Episode
Hear the full conversation with Dr. Hedrick and explore how Plus Therapeutics is working to advance the future of CNS radiotherapeutics:
Listen here: https://lnkd.in/gTrHyVXJ
Explore Our Clinical Programs
Plus Therapeutics is actively conducting clinical trials evaluating advanced radiotherapeutics for CNS cancers, including LM and GBM.
Learn more about our clinical programs here:
https://lnkd.in/gYhPXbe4
Recent Comments